Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.

Fidyt K, Pastorczak A, Goral A, Szczygiel K, Fendler W, Muchowicz A, Bartlomiejczyk MA, Madzio J, Cyran J, Graczyk-Jarzynka A, Jansen E, Patkowska E, Lech-Maranda E, Pal D, Blair H, Burdzinska A, Pedzisz P, Glodkowska-Mrowka E, Demkow U, Gawle-Krawczyk K, Matysiak M, Winiarska M, Juszczynski P, Mlynarski W, Heidenreich O, Golab J, Firczuk M.

Mol Oncol. 2019 May;13(5):1180-1195. doi: 10.1002/1878-0261.12476. Epub 2019 Apr 5.

2.

Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells.

Chlebowska-Tuz J, Sokolowska O, Gaj P, Lazniewski M, Firczuk M, Borowiec K, Sas-Nowosielska H, Bajor M, Malinowska A, Muchowicz A, Ramji K, Stawinski P, Sobczak M, Pilch Z, Rodziewicz-Lurzynska A, Zajac M, Giannopoulos K, Juszczynski P, Basak GW, Plewczynski D, Ploski R, Golab J, Nowis D.

Haematologica. 2018 Nov;103(11):1843-1852. doi: 10.3324/haematol.2018.190231. Epub 2018 Jul 12.

3.

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.

Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, Zagozdzon A, Bojarczuk K, Bobrowicz M, Siernicka M, Machnicki MM, Gobessi S, Barankiewicz J, Lech-Maranda E, Efremov DG, Juszczynski P, Calado D, Golab J, Winiarska M.

Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018.

4.

A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.

Czardybon W, Windak R, Gołas A, Gałęzowski M, Sabiniarz A, Dolata I, Salwińska M, Guzik P, Zawadzka M, Gabor-Worwa E, Winnik B, Żurawska M, Kolasińska E, Wincza E, Bugaj M, Danielewicz M, Majewska E, Mazan M, Dubin G, Noyszewska-Kania M, Jabłońska E, Szydłowski M, Sewastianik T, Puła B, Szumera-Ciećkiewicz A, Prochorec-Sobieszek M, Mądro E, Lech-Marańda E, Warzocha K, Tamburini J, Juszczyński P, Brzózka K.

Oncotarget. 2018 Mar 30;9(24):16917-16931. doi: 10.18632/oncotarget.24747. eCollection 2018 Mar 30.

5.

Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.

Białopiotrowicz E, Górniak P, Noyszewska-Kania M, Puła B, Makuch-Łasica H, Nowak G, Bluszcz A, Szydłowski M, Jabłonska E, Piechna K, Sewastianik T, Polak A, Lech-Marańda E, Budziszewska BK, Wasylecka-Juszczyńska M, Borg K, Warzocha K, Czardybon W, Gałęzowski M, Windak R, Brzózka K, Juszczyński P.

J Cell Mol Med. 2018 Jul;22(7):3548-3559. doi: 10.1111/jcmm.13632. Epub 2018 Apr 17.

6.

Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.

Szydłowski M, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Derezińska E, Hoser G, Wasilewska D, Szymańska-Giemza O, Jabłońska E, Białopiotrowicz E, Sewastianik T, Polak A, Czardybon W, Gałęzowski M, Windak R, Zaucha JM, Warzocha K, Brzózka K, Juszczyński P.

Blood. 2017 Sep 21;130(12):1418-1429. doi: 10.1182/blood-2017-01-760702. Epub 2017 Jul 11.

7.

New insights into redox homeostasis as a therapeutic target in B-cell malignancies.

Graczyk-Jarzynka A, Zagozdzon R, Muchowicz A, Siernicka M, Juszczynski P, Firczuk M.

Curr Opin Hematol. 2017 Jul;24(4):393-401. doi: 10.1097/MOH.0000000000000351. Review.

8.

MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.

Jablonska E, Gorniak P, Szydlowski M, Sewastianik T, Bialopiotrowicz E, Polak A, Warzocha K, Juszczynski P.

Exp Hematol. 2017 Feb;46:56-61.e1. doi: 10.1016/j.exphem.2016.09.011. Epub 2016 Oct 6.

PMID:
27720936
9.

MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy.

Polak A, Kiliszek P, Sewastianik T, Szydłowski M, Jabłońska E, Białopiotrowicz E, Górniak P, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Nowis D, Gołąb J, Giebel S, Lech-Marańda E, Warzocha K, Juszczyński P.

PLoS One. 2016 May 19;11(5):e0155893. doi: 10.1371/journal.pone.0155893. eCollection 2016.

10.

FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.

Sewastianik T, Szydlowski M, Jablonska E, Bialopiotrowicz E, Kiliszek P, Gorniak P, Polak A, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Kaminski TS, Markowicz S, Nowak E, Grygorowicz MA, Warzocha K, Juszczynski P.

Oncogene. 2016 Nov 17;35(46):5989-6000. doi: 10.1038/onc.2016.126. Epub 2016 May 2.

PMID:
27132507
11.

FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.

Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P.

Blood. 2016 Feb 11;127(6):739-48. doi: 10.1182/blood-2015-06-654111. Epub 2015 Nov 19.

12.

Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.

Gorniak P, Budziszewska B, Pula B, Wasylecka M, Borg K, Nowak G, Makuch-Lasica H, Lech-Maranda E, Warzocha K, Juszczynski P.

Leuk Lymphoma. 2016;57(6):1471-3. doi: 10.3109/10428194.2015.1096355. Epub 2015 Nov 16. No abstract available.

PMID:
26414098
13.

Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.

Gorniak P, Ejduk A, Borg K, Makuch-Lasica H, Nowak G, Lech-Maranda E, Prochorec-Sobieszek M, Warzocha K, Juszczynski P.

Eur J Haematol. 2016 Feb;96(2):181-7. doi: 10.1111/ejh.12566. Epub 2015 May 13.

PMID:
25891904
14.

Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.

Musialik E, Bujko M, Kober P, Grygorowicz MA, Libura M, Przestrzelska M, Juszczyński P, Borg K, Florek I, Jakóbczyk M, Siedlecki JA.

Mol Med Rep. 2015 May;11(5):3948-54. doi: 10.3892/mmr.2015.3196. Epub 2015 Jan 13.

PMID:
25585874
15.

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.

Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JH, Golab J.

MAbs. 2014;6(5):1300-13. doi: 10.4161/mabs.32106. Epub 2014 Oct 30.

16.

MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.

Sewastianik T, Prochorec-Sobieszek M, Chapuy B, Juszczyński P.

Biochim Biophys Acta. 2014 Dec;1846(2):457-67. doi: 10.1016/j.bbcan.2014.08.006. Epub 2014 Sep 6. Review.

PMID:
25199984
17.

Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.

Musialik E, Bujko M, Kober P, Grygorowicz MA, Libura M, Przestrzelska M, Juszczyński P, Borg K, Florek I, Jakóbczyk M, Baranowska A, Siedlecki JA.

Leuk Res. 2014 Jul;38(7):850-6. doi: 10.1016/j.leukres.2014.04.013. Epub 2014 May 9.

PMID:
24878001
18.

Repetitive genomic elements and overall DNA methylation changes in acute myeloid and childhood B-cell lymphoblastic leukemia patients.

Bujko M, Musialik E, Olbromski R, Przestrzelska M, Libura M, Pastwińska A, Juszczyński P, Zwierzchowski L, Baranowski P, Siedlecki JA.

Int J Hematol. 2014 Jul;100(1):79-87. doi: 10.1007/s12185-014-1592-0. Epub 2014 May 20.

PMID:
24841671
19.

FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development.

Szydłowski M, Jabłońska E, Juszczyński P.

Int Rev Immunol. 2014 Mar;33(2):146-57. doi: 10.3109/08830185.2014.885022. Epub 2014 Feb 20. Review.

PMID:
24552152
20.

SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA.

Cancer Cell. 2013 Jun 10;23(6):826-38. doi: 10.1016/j.ccr.2013.05.002.

21.

Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?

Prochorec-Sobieszek M, Nasiłowska-Adamska B, Borg K, Kopeć I, Kos-Zakrzewska K, Juszczyński P, Warzocha K.

Leuk Lymphoma. 2012 Sep;53(9):1824-7. doi: 10.3109/10428194.2012.661856. Epub 2012 Mar 13. No abstract available.

PMID:
22288769
22.

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA.

Clin Cancer Res. 2012 Mar 15;18(6):1611-8. doi: 10.1158/1078-0432.CCR-11-1942. Epub 2012 Jan 23. Erratum in: Clin Cancer Res. 2012 Apr 1;18(7):2117.

23.

Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders.

Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA.

Blood. 2011 Apr 21;117(16):4315-22. doi: 10.1182/blood-2010-11-320481. Epub 2011 Feb 7.

24.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA.

Blood. 2010 Oct 28;116(17):3268-77. doi: 10.1182/blood-2010-05-282780. Epub 2010 Jul 13.

25.

MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.

Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA.

Clin Cancer Res. 2010 Apr 1;16(7):2122-30. doi: 10.1158/1078-0432.CCR-09-2765. Epub 2010 Mar 23.

26.

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA.

Blood. 2009 Dec 17;114(26):5315-21. doi: 10.1182/blood-2009-02-204362. Epub 2009 Oct 23.

27.

BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response.

Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA.

Mol Cell. 2009 Oct 9;36(1):110-20. doi: 10.1016/j.molcel.2009.08.019.

28.

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, Takeyama K, Shipp MA.

Br J Haematol. 2009 Feb;144(3):358-66. doi: 10.1111/j.1365-2141.2008.07484.x. Epub 2008 Nov 13.

29.

Host immune response in B-cell lymphomas: friend or foe?

Juszczyński P, Nowak J, Warzocha K.

Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):245-55. doi: 10.1007/s00005-008-0028-z. Epub 2008 Jul 29. Review.

PMID:
18726146
30.

AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.

Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL.

Clin Cancer Res. 2008 Jun 1;14(11):3338-44. doi: 10.1158/1078-0432.CCR-07-4709.

31.

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA.

Blood. 2008 Feb 15;111(4):2230-7. Epub 2007 Nov 15.

32.

Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.

Nowak J, Kalinka-Warzocha E, Juszczyński P, Mika-Witkowska R, Zajko M, Graczyk-Pol E, Coiffier B, Salles G, Warzocha K.

Tissue Antigens. 2008 Jan;71(1):16-26. Epub 2007 Oct 29.

PMID:
17971052
33.

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.

Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9. Epub 2007 Aug 1.

34.

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A.

Blood. 2007 Sep 15;110(6):2067-74. Epub 2007 Jun 1.

35.

Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia?

Lech-Maranda E, Juszczynski P, Szmigielska-Kaplon A, Jamroziak K, Balcerczak E, Robak T.

Haematologica. 2007 May;92(5):710-1.

36.

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12. Epub 2007 Feb 20.

37.

Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.

Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, Salles G, Warzocha K.

Genes Chromosomes Cancer. 2007 May;46(5):500-7.

PMID:
17311253
38.
40.

[The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas].

Kalinka E, Juszczyński P, Woszczek G, Borowiec M, Robak T, Kowalski ML, Biliński P, Coiffier B, Salles G, Warzocha K.

Przegl Lek. 2005;62(12):1422-6. Polish.

PMID:
16786764
41.

[The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas].

Juszczyński P, Kalinka E, Woszczek G, Borowiec M, Robak T, Kowalski ML, Biliński P, Coiffiers B, Salles G, Warzocha K.

Przegl Lek. 2005;62(12):1417-21. Polish.

PMID:
16786763
42.

Comparison study for genotyping of a single-nucleotide polymorphism in the tumor necrosis factor promoter gene.

Juszczynski P, Woszczek G, Borowiec M, Kowalski M, Robak T, Biliński P, Salles G, Warzocha K.

Diagn Mol Pathol. 2002 Dec;11(4):228-33.

PMID:
12459639
43.

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.

Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, Kowalski M, Lech-Maranda E, Baseggio L, Coiffier B, Salles G, Warzocha K.

Blood. 2002 Oct 15;100(8):3037-40.

44.

Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia.

Juszczyński P, Niewiarowski W, Krykowski E, Robak T, Warzocha K.

Leuk Lymphoma. 2002 Jan;43(1):153-8.

PMID:
11908721

Supplemental Content

Loading ...
Support Center